Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Prostate Cancer |
Free Subscription
2 AJR Am J Roentgenol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
Reply to "Prostate Cancer Screening and Prostate MRI: Hypotheses Founded on
Uncertain Evidence".
AJR Am J Roentgenol. 2024 Mar 20. doi: 10.2214/AJR.24.31168.
PubMed
Prostate Cancer Screening and Prostate MRI: Hypotheses Founded on Uncertain
Evidence.
AJR Am J Roentgenol. 2024 Mar 20. doi: 10.2214/AJR.24.31070.
PubMed
Reply to: Letter to the editor regarding the article 'Prostate cancer outcomes
following whole-gland and focal high-intensity focused ultrasound'.
BJU Int. 2024 Mar 22. doi: 10.1111/bju.16348.
PubMed
Screening and active surveillance in prostate cancer: the dilemma continues.
BJU Int. 2024 Mar 21. doi: 10.1111/bju.16345.
PubMed
Online decision aid for patients with prostate cancer evaluated by 11 290
patients and 91 urologists in Germany.
BJU Int. 2024 Mar 20. doi: 10.1111/bju.16329.
PubMed
Abstract available
Active surveillance in all cases of screen-detected prostate cancer.
BJU Int. 2024 Mar 20. doi: 10.1111/bju.16344.
PubMed
Magnetic resonance imaging-targeted prostate biopsy changed everything (so
everything has to change).
BJU Int. 2024;133:354-355.
PubMed
Image intensifier-guided transperineal prostate biopsy for patients without a
rectum: novel technique.
BJU Int. 2024;133:487-490.
PubMed
Abstract available
Magnetic resonance imaging targeted biopsy in biopsy-naive patients and the risk
of overtreatment in prostate cancer: a grading issue.
BJU Int. 2024;133:432-441.
PubMed
Abstract available
NanoLuc Binary Technology as a methodological approach: an important new tool for
studying the localization of androgen receptor and androgen receptor splice
variant V7 homo and heterodimers.
BMC Cancer. 2024;24:346.
PubMed
Abstract available
Multivitamin use after diagnosis and prostate cancer survival among men with
nonmetastatic prostate cancer.
Br J Cancer. 2024 Mar 15. doi: 10.1038/s41416-024-02651.
PubMed
Abstract available
Effect of hormonal therapies for prostate cancer on cognition: The ongoing search
for clarity.
Cancer. 2024 Mar 16. doi: 10.1002/cncr.35283.
PubMed
Chromatin activation with H3K36me2 and compartment shift in metastatic
castration-resistant prostate cancer.
Cancer Lett. 2024;588:216815.
PubMed
Abstract available
A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with
Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
Clin Cancer Res. 2024 Mar 21. doi: 10.1158/1078-0432.CCR-23-3436.
PubMed
Abstract available
Membranous urethral length measurement on preoperative MRI to predict
incontinence after radical prostatectomy: a literature review towards a proposal
for measurement standardization.
Eur Radiol. 2024;34:2621-2640.
PubMed
Abstract available
Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage
Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate
Cancer: OLIGOPELVIS (GETUG-P07).
Eur Urol. 2024 Mar 14:S0302-2838(24)02131-6. doi: 10.1016/j.eururo.2024.
PubMed
Abstract available
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The
SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024.
PubMed
Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish
Population.
Eur Urol. 2024 Mar 14:S0302-2838(24)02141-9. doi: 10.1016/j.eururo.2024.
PubMed
Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a
Prostate Health Check: A Prospective Cohort Study.
Eur Urol. 2024;85:395.
PubMed
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease
Extent and Overall Survival of Patients with High-risk Nonmetastatic
Castration-resistant Prostate Cancer: An International Multicenter Retrospective
Study.
Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.
PubMed
Abstract available
Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml:
Results from the Goteborg-2 Prostate Cancer Screening Trial.
Eur Urol. 2024 Mar 14:S0302-2838(24)00052-6. doi: 10.1016/j.eururo.2024.
PubMed
Abstract available
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in
Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical
Trial.
Eur Urol. 2024 Mar 14:S0302-2838(24)02133-X. doi: 10.1016/j.eururo.2024.
PubMed
Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term
Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External
Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate
Cancer. Eur
Eur Urol. 2024 Mar 15:S0302-2838(24)02139-0. doi: 10.1016/j.eururo.2024.
PubMed
Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions
in Prostate Cancer Lead to Overtreatment?
Eur Urol. 2024 Mar 16:S0302-2838(24)00071-X. doi: 10.1016/j.eururo.2024.
PubMed
Abstract available
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer
(SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024.
PubMed
Abstract available
SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for
Personalized Targeted Radionuclide Cancer Therapy.
Int J Radiat Oncol Biol Phys. 2024;118:1575-1584.
PubMed
Abstract available
Long-Term Results of a Phase 1 Dose Escalation Trial of Ablative Stereotactic
Body Radiation Therapy.
Int J Radiat Oncol Biol Phys. 2024;118:1490-1496.
PubMed
Abstract available
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer
Treated With SABR in the Phase 2 SABR-5 Trial.
Int J Radiat Oncol Biol Phys. 2024;118:1497-1506.
PubMed
Abstract available
Simultaneous focal boost with stereotactic radiotherapy for localised
intermediate to high-risk prostate cancer: Primary outcomes of the SPARC phase II
trial.
Int J Radiat Oncol Biol Phys. 2024 Mar 16:S0360-3016(24)00425.
PubMed
Abstract available
Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for
Prostate Cancer.
J Clin Oncol. 2024 Mar 20:JCO2301604. doi: 10.1200/JCO.23.01604.
PubMed
Abstract available
Letter: Point of View: What Are We Doing? The Incredible Expense and Uncertain
Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
J Urol. 2024 May 19:101097JU0000000000003924. doi: 10.1097/JU.0000000000003924.
PubMed
The association between zinc and prostate cancer development: A systematic review
and meta-analysis.
PLoS One. 2024;19:e0299398.
PubMed
Abstract available
Glycoprofiling of proteins as prostate cancer biomarkers: A multinational
population study.
PLoS One. 2024;19:e0300430.
PubMed
Abstract available
VOC-based detection of prostate cancer using an electronic nose and ion mobility
spectrometry: A novel urine-based approach.
Prostate. 2024 Mar 18. doi: 10.1002/pros.24692.
PubMed
Abstract available
Other-cause mortality in incidental prostate cancer.
Prostate. 2024 Mar 20. doi: 10.1002/pros.24689.
PubMed
Abstract available
Thank you for your interest in scientific medicine.